Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.
Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.
复制标题
DOI：
10.3389/fimmu.2022.869990
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)新变种的出现使预防病毒传播变得更加困难，尽管有疫苗可用。有关突破性感染和抗体中和变种能力下降的报道提出了一个问题，即目前的疫苗是否仍能预防新冠肺炎病。应用活化诱导标记物分析和Th1型细胞因子产生的方法，研究了BNT162b2新冠肺炎基因疫苗免疫医护人员和新冠肺炎患者外周血单个核细胞T细胞应答的动态和持续性。我们证明，尽管抗体水平下降，但接种疫苗和感染后，对Alpha、Beta、Gamma和Delta变种的同样高的T细胞反应至少持续6个月。
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants raise the question whether current vaccines can still protect against COVID-19 disease. We studied the dynamics and persistence of T cell responses using activation induced marker (AIM) assay and Th1 type cytokine production in peripheral blood mononuclear cells obtained from BNT162b2 COVID-19 mRNA vaccinated health care workers and COVID-19 patients. We demonstrate that equally high T cell responses following vaccination and infection persist at least for 6 months against Alpha, Beta, Gamma, and Delta variants despite the decline in antibody levels.